According to the release, Mayo Clinic’s new funding in Numares would hasten the delivery of tests assessing renal function and heart risk that are anticipated to get the U.S. FDA’s approval in the beginning of the upcoming year. The AI tools will allow physicians to provide better treatment for patients with chronic illnesses, such as kidney and heart disorders, by using algorithms to assess various biomarkers that are used to track disease development in patients.
Mayo Clinic also intends to support other AI technological platforms for creating diagnostic tools for other ailments related to the liver and brain. Numares’ CEO, Winton Gibbons, says that Mayo Clinic’s support has given them a nudge toward their aim of improving patient care.
Read More from HealthcareITNews